Secreted protein acidic and rich in cysteine (SPARC) is associated with nasopharyngeal carcinoma metastasis and poor prognosis

[1]  M. West,et al.  Gene expression profiling and genetic markers in glioblastoma survival. , 2005, Cancer research.

[2]  P. Delmas,et al.  Immunological screening of SPARC/Osteonectin in nonmineralized tissues. , 1992, Bone.

[3]  Zhang Feng,et al.  A new staging system for nasopharyngeal carcinoma in China. , 1994, International journal of radiation oncology, biology, physics.

[4]  B. le Bail,et al.  Osteonectin/SPARC is overexpressed in human hepatocellular carcinoma , 1999, The Journal of pathology.

[5]  S. Sleijfer,et al.  Association of an Extracellular Matrix Gene Cluster with Breast Cancer Prognosis and Endocrine Therapy Response , 2008, Clinical Cancer Research.

[6]  M. Tang,et al.  SPARC in cancer biology: its role in cancer progression and potential for therapy. , 2008, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[7]  D. Massi,et al.  Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. , 1999, Human pathology.

[8]  B. O'Sullivan,et al.  Nasopharyngeal carcinoma: the next challenges. , 2010, European journal of cancer.

[9]  G. Tse,et al.  High frequency of chromosome 3p deletion in histologically normal nasopharyngeal epithelia from southern Chinese. , 2000, Cancer research.

[10]  A. Miyauchi,et al.  Gene expression profiles in thyroid carcinomas , 2000, British Journal of Cancer.

[11]  G. Watkins,et al.  Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. , 2005, Prostaglandins, leukotrienes, and essential fatty acids.

[12]  F. Rödel,et al.  Stromal SPARC expression and patient survival after chemoradiation for non-resectable pancreatic adenocarcinoma , 2008, Cancer biology & therapy.

[13]  R. Tibshirani,et al.  Gene expression profiling identifies clinically relevant subtypes of prostate cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[14]  M. Hsu,et al.  Nasopharyngeal carcinoma in Taiwan clinical manifestations and results of therapy , 1983, Cancer.

[15]  J. Squire,et al.  Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma , 2006, BMC Cancer.

[16]  S. Stefani,et al.  Distant metastases of nasopharyngeal carcinoma: A study of 256 male patients , 1986, Journal of surgical oncology.

[17]  E. Sage,et al.  SPARC and tumor growth: Where the seed meets the soil? , 2004, Journal of cellular biochemistry.

[18]  M. Zeng,et al.  Pre-malignant nasopharyngeal epithelial cell models. , 2009, Ai zheng = Aizheng = Chinese journal of cancer.

[19]  J. Shao,et al.  Epstein-Barr virus encoded latent membrane protein 1 regulates mTOR signaling pathway genes which predict poor prognosis of nasopharyngeal carcinoma , 2010, Journal of Translational Medicine.

[20]  Chin-Tarng Lin,et al.  Transcription factor SOX‐5 enhances nasopharyngeal carcinoma progression by down‐regulating SPARC gene expression , 2007, The Journal of pathology.

[21]  S Hsueh,et al.  Overexpression of SPARC gene in human gastric carcinoma and its clinic–pathologic significance , 2004, British Journal of Cancer.

[22]  Jun Ma,et al.  A comparison of the Chinese 1992 and fifth‐edition International Union Against Cancer staging systems for staging nasopharyngeal carcinoma , 2000, Cancer.

[23]  S. Dhanasekaran,et al.  Delineation of prognostic biomarkers in prostate cancer , 2001, Nature.

[24]  C. Gondi,et al.  SPARC-induced migration of glioblastoma cell lines via uPA-uPAR signaling and activation of small GTPase RhoA. , 2006, International journal of oncology.

[25]  A. Sav,et al.  Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas , 2009, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[26]  C. Iacobuzio-Donahue,et al.  Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Wee,et al.  Prognostic factors in 677 patients in Singapore with nondisseminated nasopharyngeal carcinoma , 1999, Cancer.

[28]  P. Parsons,et al.  Novel markers for poor prognosis in head and neck cancer , 2005, International journal of cancer.

[29]  B. O'Sullivan.  Nasopharynx cancer: therapeutic value of chemoradiotherapy. , 2007, International journal of radiation oncology, biology, physics.

[30]  Yun-Fei Xia,et al.  Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. , 2006, Cancer research.

[31]  J. Ma,et al.  A new staging system for nasopharyngeal carcinoma in China. , 1994, International journal of radiation oncology, biology, physics.

[32]  O. Volpert,et al.  SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis. , 2002, Cancer research.

[33]  D. Oh,et al.  Matricellular proteins in the trabecular meshwork. , 2009, Experimental eye research.

[34]  Y. Nagashima,et al.  Expression of SPARC in tongue carcinoma of stage II is associated with poor prognosis: an immunohistochemical study of 86 cases. , 2005, International journal of molecular medicine.

[35]  M. Mori,et al.  Clinical significance of secreted protein acidic and rich in cystein in esophageal carcinoma and its relation to carcinoma progression , 2003, Cancer.

[36]  E Helene Sage,et al.  Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. , 2003, Cancer research.

[37]  T. Yoshizaki,et al.  System for Nasopharyngeal Carcinoma: Comparison of Fourth and Fifth Editions of UICC TNM Classification , 2000, The Annals of otology, rhinology, and laryngology.

[38]  Qiong Shao,et al.  MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. , 2008, RNA.

[39]  S. Rempel,et al.  A study of SPARC and vitronectin localization and expression in pediatric and adult gliomas: high SPARC secretion correlates with decreased migration on vitronectin. , 2000, International journal of oncology.

[40]  A. Gown,et al.  Distribution of SPARC in normal and neoplastic human tissue. , 1995, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[41]  T. Tursz,et al.  Leukemoid reaction, bone marrow invasion, fever of unknown origin, and metastatic pattern in the natural history of advanced undifferentiated carcinoma of nasopharyngeal type: a review of 255 consecutive cases. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  T. Sørlie,et al.  Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome , 2008, The Journal of pathology.

[43]  Chan Yl.  Nasopharyngeal carcinoma in Taiwan , 1992 .

[44]  H. Kanayama,et al.  Analysis of the gene expression of SPARC and its prognostic value for bladder cancer. , 2001, The Journal of urology.

[45]  M. Yao,et al.  SPARC expression in primary human renal cell carcinoma: upregulation of SPARC in sarcomatoid renal carcinoma. , 2001, Human pathology.

[46]  B. Baraňska,et al.  Formation of the nemaline structures in soleus muscle of rats subjected to long-lasting immobilization. , 1999, Folia morphologica.

[47]  C. J. Chen,et al.  Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. , 2001, The New England journal of medicine.

[48]  Pelayo Vilar,et al.  Nasopharyngeal Carcinoma , 1966 .

[49]  E. Sage,et al.  A prototypic matricellular protein in the tumor microenvironment—Where there's SPARC, there's fire , 2008, Journal of cellular biochemistry.

[50]  R L Vessella,et al.  Differential expression of osteonectin/SPARC during human prostate cancer progression. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[51]  J. Sham,et al.  The predictive value of the 1997 American Joint Committee on Cancer stage classification in determining failure patterns in nasopharyngeal carcinoma , 2001, Cancer.

[52]  Andrea S. Llera,et al.  The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host , 2008, Cancer and Metastasis Reviews.

[53]  J. A. Greenwood,et al.  Signaling of de‐adhesion in cellular regulation and motility , 1998, Microscopy research and technique.

[54]  Z. Ye,et al.  SPARC Is Associated with Gastric Cancer Progression and Poor Survival of Patients , 2009, Clinical Cancer Research.